A Phase 4 interventional study of Mirikizumab in Crohn Disease, sponsored by Alimentiv Inc.. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Alimentiv Inc. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing mirikizumab in Crohn Disease — 7 open to participants now, 8 under way, 3 of them phase 3. mirikizumab · Crohn Disease.
Among the 10 studies testing mirikizumab in Crohn Disease, this one is the 9th largest by planned enrollment, is one of 4 that started in 2026, is one of 5 in phase 4, and was the 6th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →7 of the 10 studies testing mirikizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18–75
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–17
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–19
Specialty Networks Research. · Sites in United States
Ages 21+
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
By country, each count listing its studies:
mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 60 is below the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 150 across the 10 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 6 most frequent:
Alimentiv Inc. is the lead sponsor of 12 studies on the registry; 4 are open to participants now.
Alimentiv Inc. has 7 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
2 of the studies testing mirikizumab in Crohn Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06997965Alimentiv Inc.Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD | 2027-09-01 |
| NCT07292012Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesEfficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing mirikizumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, single-arm, phase 4 study to assess the safety and efficacy of mirikizumab in approximately 60 participants with stricturing CD.
This is an open-label, single-arm, phase 4 study to assess the efficacy of mirikizumab in 18 years of age) with a diagnosis of ileal or ileocolonic CD based upon radiologic, clinical, endoscopic, and histologic evidence with tolerable obstructive symptoms. Participants will be recruited from approximately 25 sites in 3 countries (Canada, the United Kingdom [UK] and the United States [US]).
This study consists of 3 study periods (screening period, open-label treatment period, and safety follow-up). After signing informed consent, potential study participants will be screened over a 5- week screening period, including magnetic resonance enterography (MRE) and ileocolonoscopy to confirm the presence of inflammatory strictures. Eligible participants will receive 900 mg mirikizumab intravenously (IV) on Day 1 every 4 weeks (Q4W) to Week 8, and then 300 mg mirikizumab subcutaneously (SC) Q4W from Week 12 to Week 24. The primary endpoint will be assessed at Week 24.
During the screening visit, MRE will be used to confirm the presence of stricture with areas of edema, which represents a specific sign of moderate-to-severe histologic inflammation. Edema appears as areas of high signal intensity on T2 sequences with selective fat suppression.
During screening and Week 24 visits, participants will undergo blinded MRE disease activity assessment with the MaRIA and simplified MaRIA (sMaRIA) score and assessment of stricture items. At the same time points, ileocolonoscopy with biopsy collection (2 from the ileum and 2 from each of ascending, transverse, and descending colon and rectum segments, and 2 within [if feasible] or as close to the stricture of the terminal ileum as possible; 12 biopsies total) will be performed for blinded endoscopic and histopathologic disease activity assessments with the SES- CD and Robarts Histopathology Index (RHI), respectively.
Throughout the study, participants will undergo routine safety assessments at clinic visits, which will include physical examination, clinical laboratory assessment, and recording of serious adverse events (SAEs). At specified time points throughout the study, participants will complete patient-reported items of the CDAI/2-item PRO (PRO2)/ Harvey-Bradshaw Index (HBI), CD Obstructive Score (CDOS), stricture symptom-related questions, fecal Urgency Numerical Rating Scale (UNRS), Patient Global Impressions of Severity (PGI-S), PGI of Change (PGI-C), Short Inflammatory Bowel Disease Questionnaire (SIBDQ), and Symptoms and Impacts Questionnaire for CD (SIQ-CD) questionnaires in an electronic study diary for 7 days. Blood samples will be collected during screening and at Weeks 12 and 24 for safety laboratory and C-reactive protein (CRP) assessments. Stool samples will be collected at baseline and Week 24 for assessing fecal calprotectin (FCP) levels.
Participants will undergo a safety follow-up visit 4 weeks after the last dose of study treatment for safety assessments and recording of SAEs, severe liver injury (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] 3 × upper limit of normal [ULN]), serious infections, and CD- related complications. The safety follow-up visit can be performed by telephone, unless the participant has any ongoing AEs that require follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Presence of at least 1 inflammatory stricture in the terminal ileum* within reach of an endoscope (passable or nonpassable). Strictures should be noncritical, naïve or anastomotic stricture(s), caused by CD and confirmed centrally by MRE according to the following criteria:
Participants can be on stable background therapy for CD and must agree to maintain the background therapy during the study. Acceptable stable background therapies include:
Exclusion Criteria:
CD-related complications:
Liver chemistry parameters that exceed the following thresholds:
Concomitant use of the following medications during the screening period or throughout the study:
Systemic or opportunistic infections including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label mirikizumab 900mg IV Weeks 0,4, and 8 then mirikizumab 300mg SC Weeks 12, 16, 20, and 24.
Drug: Mirikizumab
Mirikizumab is an IL-23 antagonist.
Also known as: Omvoh
To evaluate the efficacy of mirikizumab in inducing a radiologic response in participants with inflammatory stricturing CD
Achievement of radiologic response (defined by a 25% improvement in stricture length and no worsening of prestenotic small bowel diameter or wall thickness OR 25% improvement in prestenotic small bowel diameter and no worsening of stricture length or wall thickness)
Time frame: At week 24
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change in baseline in CDOS score
Time frame: At week 12
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in CDOS score
Time frame: At week 24
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in CDAI score
Time frame: At week 12
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in CDAI score
Time frame: At week 24
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in PRO2 Score
Time frame: At week 12
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in PRO2 score
Time frame: At week 24
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in HBI score
Time frame: At week 12
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in HBI score
Time frame: At week 24
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Achievement of endoscopic response (defined by ≥ 50% reduction from baseline in SES-CD score) AND radiographic improvement (defined by a ≥ 25% improvement from baseline in stricture MaRIA score)
Time frame: At week 24
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Achievement of endoscopic response (defined by ≥ 50% reduction from baseline in SES-CD score)
Time frame: At week 24
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in SIBDQ score
Time frame: At week 24
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in UNRS score
Time frame: At week 12
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in UNRS score
Time frame: At week 24
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in RHI score
Time frame: At week 24
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Achievement of histological response (defined by a ≥ 50% reduction from baseline in RHI score)
Time frame: At week 24
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Achievement of CRP response (defined by ≥ 50% reduction from baseline in CRP levels)
Time frame: At week 12
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Achievement of CRP response (defined by ≥ 50% reduction from baseline in CRP levels)
Time frame: At week 24
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in CRP level
Time frame: At week 12
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in CRP level
Time frame: At week 24
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Achievement of FCP response (defined by ≥ 50% reduction from baseline in FCP level)
Time frame: At week 24
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in FCP level
Time frame: At week 24
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in PGI-S score
Time frame: At week 4
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in PGI-S score
Time frame: At week 8
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in PGI-S score
Time frame: At week 12
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in PGI-S score
Time frame: At week 16
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in PGI-S score
Time frame: At week 20
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
Change from baseline in PGI-S score
Time frame: At week 24
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
PGI-S score
Time frame: At week 4
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
PGI-S score
Time frame: At week 8
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
PGI-S score
Time frame: At week 12
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
PGI-S score
Time frame: At week 16
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
PGI-S score
Time frame: At week 20
To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD
PGI-S score
Time frame: At week 24
To evaluate the safety of mirikizumab in participants with stricturing CD
Occurrence of SAEs, severe liver injury (ALT or AST ≥ 3 × ULN), and serious infections
Time frame: Through end of safety follow-up
To evaluate the safety of mirikizumab in participants with stricturing CD
CD-related complications
Time frame: Through end of safety follow-up defined as a composite of (1) CD-related surgery, (2) CD-related hospitalization, (3) CD-medication-related complication, and (4) rescue therapy for a documented CD-related flare
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Started Apr 2026 (actual). Primary completion is estimated for Sep 2027, 16 months after the start.
Of 54 non-industry phase 4 interventional studies under Crohn Disease, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 71. This study's planned 16 months is below that.
Counting every sponsor, half of 70 studies reached it within 56 months; a quarter within 35 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab
Alimentiv Inc.